PAVmed Inc. (PAVM): Entry into a Material Definitive Agreement
PAVmed Inc. (PAVM) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry Into a Material Definitive Agreement. On September 9, 2026, PAVmed Inc. (the “ Company ”) entered into a Sales Agreement (the “ Agreement ”) with A.G.P./Alliance Global Partners, as sales agent (the “ Agent ”), pursuant to which the Company may offer and sell, fr
How this was made
The 30-second read
Why it matters
The capital raise provides immediate liquidity for working capital but may dilute existing shareholders.
Market read
Primary disclosure of a micro‑cap equity raise; relevant for short‑term traders and dilution‑aware investors.
What to watch
Potential strategic partnership with the sales agent could bring future deals.
Background
PAVmed Inc. (PAVM) disclosed a material definitive agreement to sell up to $9.4 million of common stock through an at‑the‑market offering.
Ticker impact
PAVmed filed an 8‑K announcing a $9.4 million at‑the‑market offering agreement with Alliance Global Partners.
Short‑term upside as capital is raised, long‑term pressure from dilution.
The filing is the first public disclosure of the raise; investors will price in the cash and dilution immediately.
Market effects
Adds modest supply of equity in the biotech/health‑tech sector.
Limited to U.S. micro‑cap market.
Low
Counterpoint
The raise may signal cash‑flow stress, suggesting a short bias.
Key entities
- companyPAVmed Inc.
Issuer of the at‑the‑market offering.
- companyAlliance Global Partners
Sales agent for the offering.
